Table 1.
Baseline characteristics of the 326 patients.
| Factor | |
|---|---|
| Gender (male/female) | 164/162 |
| Age (years) | 71 (18–93) |
| Height (cm) | 158 (133–176) |
| Body weight (kg) | 57.2 (29.0–102.5) |
| Itching period (months) | 4.0 (0.25–120) |
| HCV/PBC/Alc/NASH/HBV/AIH/Overlap/Others | 114/62/47/41/21/11/6/24 |
| Child–Pugh classification A/B/C | 192/84/50 |
| Hepatocellular carcinoma (presence/absence) | 60/266 |
| Ascites (none/mild/moderate) | 255/41/30 |
| Hepatic encephalopathy (none/grade I–II/grade III–IV) | 284/31/11 |
| Past history of spontaneous bacterial peritonitis (yes/no) | 2/324 |
| Past history of variceal bleeding (yes/no) | 3/323 |
| White blood cell (/mm3) | 4800 (1100–21,330) |
| Hemoglobin (g/dL) | 11.7 (6.7–18.7) |
| Platelet (× 103/mm3) | 126 (23–549) |
| PT (%) | 80.6 (6.7–173) |
| Albumin (g/dL) | 3.5 (1.5–4.8) |
| AST (U/L) | 37 (3–1177) |
| ALT (U/L) | 25 (2–1509) |
| Total bilirubin (mg/dL) | 1.0 (0.2–29.0) |
| ALP (U/dL) | 391 (75–4600) |
| γ-GTP (mg/dL) | 47 (9–1769) |
| BUN (mg/dL) | 17.0 (4.8–143.2) |
| Creatinine (mg/dL) | 0.84 (0.33–11.7) |
| eGFR (mL/min/1.73 m2) | 61.0 (3.9–140.2) |
| AFP (ng/mL) | 4.3 (0.7–180,434) |
| M2BPGi (C.O.I.) | 2.66 (0.42–18.2) |
| FIB-4 index | 3.84 (0.52–31.0) |
| ALBI score | − 2.17 (− 3.53 to 0.67) |
| MELD score | 11.1 (6–30) |
Data are presented as numbers or medians (ranges).
HCV hepatitis C virus, PBC primary biliary cholangitis, Alc alcoholic hepatitis, NASH non-alcoholic steatohepatitis, HBV hepatitis B virus, AIH autoimmune hepatitis, PT prothrombin time, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, γ-GTP gamma glutamyl transpeptidase, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, AFP α-fetoprotein, M2BPGi Mac-2 binding protein glycosylation isomer, FIB-4 fibrosis-4, ALBI score albumin–bilirubin score, MELD score model for end-stage liver disease score.